An interventional study of Photobiomodulation in IVF Outcomes, sponsored by Columbia University. Recruiting at 1 site in United States. Open to female participants aged 18 Years to 48 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-09.
Sponsored by Columbia University · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 395 studies in Infertility with a site in United States — 62 open to participants now, 84 under way, 7 of them phase 3. Infertility · United States.
Among the 395 studies in Infertility with a site in United States, this one is the 52nd largest by planned enrollment of the 274 interventional ones that give a count, is one of 17 that started in 2026, is one of 168 with no phase, reaches primary completion later than 34 of the 82 other live ones, and was the 386th registered.
2,090 studies on the registry are indexed under Infertility; 355 are open to participants now.
Browse Infertility studies →62 of the 395 studies in Infertility with a site in United States are open now. Recruiting first, the newest first:
Abigail Mancuso · Sites in United States
Ages 18–45
Brigham and Women's Hospital · Sites in United States
Ages 18–40 · Women only · Healthy volunteers
Kevin Doody · Sites in United States
Ages 18–35 · Women only
University of Oklahoma · Sites in United States
Ages 18–45 · Women only
Reproductive Medicine Associates of New Jersey · Sites in United States
Ages 18–42 · Women only
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 232 Infertility studies recruiting now, 43 (19%) set no upper age limit and 183 (79%) stop at 75 or younger; 27 take children under 18; 74 take healthy volunteers.
This study: 18 Years to 48 Years · female · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
395 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 19 · Phase 2 32 · Phase 3 31 · Phase 4 35
First in 1989; this study’s year is marked. 17 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 270 is above the median of 133 across 1,415 interventional studies indexed under Infertility.
Median enrollment 84 across the 274 interventional studies, 150 across the 119 observational. Of the 252 that completed or were terminated, 57 (23%) have results posted.
This tab as a report to print or save as PDF → With an account.
91 of 395 have an industry lead sponsor. The 10 most frequent:
Columbia University is the lead sponsor of 1,136 studies on the registry; 194 are open to participants now.
Of its 182 completed or terminated interventional studies of FDA-regulated products, 150 (82%) have results posted.
Columbia University has 2 studies filed under Infertility — fewer than ten, so there is no comparison to draw.
25 of the studies in Infertility with a site in United States that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06375811Phase 3Yale UniversityPre-IVF Treatment With a GnRH Antagonist in Women With endometriosis_temp | 2027-03-31 |
| NCT06858111Phase 3Gameto, Inc.Fertilo In Vitro Research Study and Trial | 2027-05 |
| NCT04544462Genomic Prediction Inc.ANXA5 M2 Haplotyping in IVF Patients and Embryos | 2026-11 |
| NCT07083700Inception Fertility Research Institute, LLCFrame Support Study | 2026-12 |
| NCT02573415The Cleveland ClinicUterine Transplantation for the Treatment of Uterine Factor Infertility | 2026-12 |
Add all 25 to your calendar (.ics) → With an account.
Among the 395 studies in Infertility with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
As women get older, the "power plants" of the cells (called mitochondria) don't work as well. This makes it harder for eggs and embryos to develop normally. One possible way to help is with a gentle light treatment called photobiomodulation (PBM). This uses a special type of red light that boosts energy production in cells and helps them stay healthy. This study will test whether adding this light treatment during in vitro fertilization (IVF) can improve embryo growth and pregnancy outcomes.
Embryo development is highly energy-dependent, and impaired mitochondrial function is a well-established hallmark of reproductive aging. As women age, reactive oxygen species (ROS) accumulate and cause mitochondrial DNA (mtDNA) damage, leading to reduced oxidative phosphorylation, ATP (Adenosine 5'-triphosphate) depletion, and developmental arrest of embryos. Enhancing mitochondrial function represents a promising strategy to improve embryo quality, particularly in women of advanced maternal age.
Photobiomodulation (PBM), also known as low-level light therapy (LLLT), involves the application of low-intensity red or near-infrared (NIR) light to modulate mitochondrial activity. NIR light specifically activates cytochrome c oxidase, leading to increased ATP production, reduced oxidative stress, and improved cellular resilience. Numerous preclinical studies, including isolated mitochondria, cell cultures, and in vivo animal models, have confirmed the safety and efficacy of NIR light in restoring mitochondrial function without inducing DNA damage or chromosomal abnormalities.
The investigators previously conducted IRB-approved laboratory studies using mouse and donated human embryos, demonstrating that brief exposure to PBM improved blastocyst formation without adversely affecting chromosomal status.
The current study builds upon this foundational work to evaluate the clinical impact of PBM at the oocyte stage. In a randomized, blinded, sibling-embryo design, the investigators will test whether PBM improves fertilization rates, blastocyst formation, embryo quality, and pregnancy outcomes in participants undergoing IVF or ICSI (Intracytoplasmic sperm injection) with PGT-A (preimplantation genetic testing for aneuploidy) using their autologous oocytes.
The criteria were revised on the registry on Nov 9, 2026. See what changed
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Participants will receive the same treatment (IVF/ICSI cycles with PGT-A). Participant's resultant cleavage stage embryos will be randomized to not receive PBM.
Participants will receive the same treatment (IVF/ICSI cycles with PGT-A). Participant's resultant cleavage stage embryos will be randomized to receive PBM.
Other: Photobiomodulation
Photobiomodulation (PBM): also known as low-level light therapy (LLLT), involves the application of low-intensity red or near-infrared (NIR) light to modulate mitochondrial activity.
Number of usable blastocysts
Usable blastocysts are defined as blastocysts that can be biopsied and frozen on Day 5, 6, or 7 of development for PGT-A (pre-implantation genetic testing for aneuploidy). The study will calculate the usable blastocyst rate per oocyte retrieved defined as the number of usable blastocysts per cleavage stage embryo on Day 3.
Time frame: Seven days post egg retrieval
Time to 2-cell stage
Time (hours) for embryo to reach the 2-cell stage from insemination/ICSI as assessed by embryology using time-lapse imaging.
Time frame: Up to seven days post egg retrieval
Time to 3-cell stage
Time (hours) for embryo to reach the 3-cell stage from insemination/ICSI as assessed by embryology using time-lapse imaging.
Time frame: Up to seven days post egg retrieval
Time to 6-cell stage
Time (hours) for embryo to reach the 6-cell stage from insemination/ICSI as assessed by embryology using time-lapse imaging.
Time frame: Up to seven days post egg retrieval
Time to 8-cell stage
Time (hours) for embryo to reach the 8-cell stage from insemination/ICSI as assessed by embryology using time-lapse imaging.
Time frame: Up to seven days post egg retrieval
Time to morula
Time (hours) for embryo to reach the morula stage from insemination/ICSI as assessed by embryology using time-lapse imaging.
Time frame: Up to seven days post egg retrieval
Time to start of blastulation
Time (hours) for embryo to start blastulation from insemination/ICSI as assessed by embryology using time-lapse imaging.
Time frame: Up to seven days post egg retrieval
Time to blastocyst
Time (hours) for embryo to reach the blastocyst stage from insemination/ICSI as assessed by embryology using time-lapse imaging.
Time frame: Up to seven days post egg retrieval
Time to hatching blastocyst
Time (hours) for embryo to reach the hatching blastocyst stage from insemination/ICSI as assessed by embryology using time-lapse imaging.
Time frame: Up to seven days post egg retrieval
Number of good quality blastocysts as defined by Gardner grading system
Final blastocyst quality at the time of cryopreservation (Day 5,6, or 7) will be assessed using the Gardner grading system, which consists of three parameters: expansion and hatching status (graded 1-6), inner cell mass (graded A-D), and trophectoderm (graded A-D). A good quality blastocyst will be defined as a blastocyst of grade 3BB or higher.
Time frame: Up to seven days post egg retrieval
Euploidy Rate
The chromosomal ploidy status of cryopreserved blastocysts is assessed by the presence of two copies of each autosome and the expected complement of sex chromosomes. The euploidy rate is defined as the number of cryopreserved blastocysts that have the correct number of chromosomes divided by the total number of cryopreserved blastocysts.
Time frame: Within 30 days post egg retrieval
Proportion of Embryo Selected for Transfer
In cases with no stated embryo sex preference, the proportion of cycles in which the embryo selected for transfer is from the PBM-treated group versus the control group will be reported.
Time frame: Within 1 year post egg retrieval
Implantation Rate
Implantation rate is defined as the number of cycles with positive beta hCG (human chorionic gonadotropin) nine days or more post frozen embryo transfer divided by the total number of frozen embryo transfer cycles.
Time frame: Within 1 year post egg retrieval
Clinical pregnancy rate
Clinical pregnancy rate is defined as the number of cycles with the presence of a gestational sac visualized on transvaginal ultrasound divided by the total number of frozen embryo transfer cycles.
Time frame: Within 1 year post egg retrieval
Miscarriage rate
Miscarriage rate is defined as the number of cycles with clinical pregnancy losses divided by the number of cycles that had positive hCGs post frozen embryo transfer.
Time frame: Within 1 year of egg retrieval
Live birth rate
Live birth rate is defined as the number of cycles with a live born infant after 24 weeks gestation divided by total number of frozen embryo transfer cycles.
Time frame: Up to 2 years post egg retrieval
Gestational Age at Delivery
Total number of completed weeks and days of pregnancy, calculated using frozen embryo transfer date.
Time frame: Up to 2 years post egg retrieval
Birthweight
The weight of the baby at birth in grams
Time frame: Up to 2 years post egg retrieval
Plan to share: Undecided
No publications or documents are linked to this record.
Started Mar 2026 (actual). Primary completion is estimated for Jun 2027, 14 months after the start.
Of 385 non-industry interventional studies with no phase under Infertility, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 43. This study's planned 14 months is below that.
Counting every sponsor, half of 415 studies reached it within 24 months; a quarter within 10 and three quarters within 42.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.